[Early adjuvant intraportal chemotherapy after hepatectomy for metastases of colorectal origin].
EAIPC was tested in a preliminary study, with continuous 600 mg/m2/day 5 FU with twelve consecutive patients after curative hepatectomies for colo-rectal metastases. The aim of this study is to reduce the frequency of recurrences inside the remaining liver. The numerous reasons explaining this kind of treatment are detailed. Results about technic problems and tolerance are analysed. This work should be initiate a prospective randomized study to evaluate the efficiency of the EAIPC.
D003110:Colonic Neoplasms; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage*; D006498:Hepatectomy; D006801:Humans; D007263:Infusions, Parenteral; D008113:Liver Neoplasms / Q000517:prevention & control / Q000556:secondary*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011168:Portal System; D012004:Rectal Neoplasms; D013997:Time Factors
D005472:Fluorouracil
Chimiothérapie intraportale adjuvante précoce (CIPAP) après hépatectomie pour métastases d'origine colo-rectale.